AMD Up, NVDA Down: Upside, Downside Movers in the Morning
Upside
– $CKX +61% ($1B cash equity investment led by Brad Jacobs includes a planned $10.13-per-share pre-closing dividend)
– $CECO +45% (Q3 beat, FY27 revenue and EBITDA outlooks topped expectations and the FY26 orders view was raised)
– $GFR +38% (agrees to be acquired by Strathcona Resources)
– $HRTX +29%, $CRMD +3.5% (CorMedix agrees to acquire substantially all Heron assets for $145M upfront)
– $EDSA +23% (exclusive collaboration and licensing agreement with Kyorin for paridiprubart)
– $VIR +10% (Phase 3 ECLIPSE 1 trial met its primary endpoint, alongside expanded positive Phase 2 SOLSTICE data)
– $KGS +8.0% (Q3 beat and FY adjusted EBITDA and discretionary cash-flow guidance was raised)
– $QXO +5.9% (preliminary Q3 sales rose 79% and adjusted EBITDA increased 85%, aided by acquisitions)
– $ASTS +3.8% (forms Rakuten AST joint venture to build a direct-to-device satellite network in Japan)
– $UAL +3.9%, $DAL +3.8%, $JBLU +3.9%, $AAL +3.6% (airlines rise as crude prices drop roughly 4%)
– $KGC +3.6%, $WPM +3.3%, $NEM +2.8%, $AEM +2.8% (gold miners rise as bullion advances and the dollar weakens)
– $AMD +3.5% (rebounds from last week’s AI-chip selloff as technology futures stabilize)
– $B +2.2% (Q3 profit beat, gold production increased and FY production guidance was maintained)
– $CEG +1.7% (Q3 beat and FY adjusted EPS guidance was raised above expectations)
Downside
– $ZURA -69% (Phase 2 TibuSHIELD study in hidradenitis suppurativa failed its primary endpoint)
– $SOC -44% (Q3 revenue missed, second-half oil-sales guidance was withdrawn and the filing raised going-concern concerns)
– $PLCE -39% (files for Chapter 11 protection and begins a sale process)
– $IONS -24% (quarterly revenue beat, but FY revenue guidance came in below Street expectations)
– $CEVA -14% (Q3 revenue and adjusted EPS missed expectations)
– $FTH -14% (positive Phase 2 PIKTOR data fell short of elevated expectations, with a 33% confirmed response rate and 64% grade 3-or-higher treatment-related adverse events)
– $TNXP -14% (TONMYA sales grew, but commercialization spending drove a wider loss and the share count more than doubled year over year)
– $ABEO -11% (quarter missed while a pipeline acquisition funded with $20M of stock and a $30M private placement added dilution)
– $MNDY -6.9% (Q3 beat, but the Q4 revenue outlook came in light)
– $UNIT -6.0% (record bookings and a revenue-guide raise were outweighed by a large Q3 net loss and heavy interest expense)
– $NVDA -5.5% (board investigation involving CEO Jensen Huang raises leadership and governance uncertainty)
– $IREN -4.1% (JPMorgan cuts its target on lower capex and project delays as Bitcoin weakness adds pressure)
– $CRCL -3.2%, MARA -1.8%, MSTR -3.2% (crypto-linked stocks fall as Bitcoin trades near a two-month low)
– $DKNG -2.9% (JPMorgan downgrades to Neutral, removes the stock from its Focus List and cuts its target to $21)
– $PDD -1.8% (Morgan Stanley downgrades to Equal-Weight and cuts its target to $90 from $129)
